Compare Monster Beverage Corp (MNST) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Philip Morris International Inc. — how do they compare? Monster Beverage Corp trades at $43.66 (market cap $85.51B), while Philip Morris International Inc. trades at $201 (market cap $312.50B). The key difference: Philip Morris International Inc. is far larger — about 3.7× Monster Beverage Corp's market cap, and Philip Morris International Inc. pays a 3.19% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Monster Beverage Corp for 72 Days and Philip Morris International Inc. for 85 Days on average.
| MNST | PM | |
|---|---|---|
Market Cap | $85.51B | $312.50B |
Volume | 8,569,709 | 5,517,172 |
Sector | Consumer Staples | Consumer Staples |
52-Week High | $49.97 | $200.50 |
52-Week Low | $33.16 | $144.33 |
Typical Hold Time | 72 Days | 85 Days |
Enterprise Value | $83.81B | $355.62B |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $43.58, up 1.63% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.30, and maintains robust profitability with a net margin of 23.08% and zero long-term debt. Recent news highlights international sales growth of 35% in Q2 and a 1:2 stock split effective August 2026.
Outlook remains positive with a consensus price target of $98.22, implying significant upside, supported by international expansion and a debt-free balance sheet. Risks include competitive pressures, regulatory challenges in markets like India, and rich valuation multiples such as a P/E of 40.42. Analyst consensus is bullish with 52% buy ratings.
Philip Morris International (PM) trades at $192.69, up 1.2% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 EPS beat expectations at $2.20 vs. $2.05, and revenue growth accelerated to $40.65B in 2025. The company's smoke-free products now drive 42% of revenue, with ZYN and IQOS expansions fueling optimism. Cash flow remains robust, with 2026 operating cash flow projected at $14.3B, supporting dividend growth.
Outlook is positive given earnings momentum and smoke-free transition, but high debt ($42.17B long-term) and regulatory risks persist. The consensus price target of $212.17 implies ~10% upside, though valuation multiples are elevated versus peers. Key risks include FX volatility and slower adoption of next-gen products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
